24/7 Market News Snapshot 15 July, 2025 – Briacell Therapeutics Corp. Common Shares (NASDAQ:BCTX)
DENVER, Colo., 15 July, 2025 (www.247marketnews.com) – (Nasdaq:BCTX) are discussed in this article.
BriaCell Therapeutics Corp. (Nasdaq:BCTX, BCTXW, BCTXZ; TSX:BCT) has experienced a noteworthy decline in its stock price, dropping to $0.777 per share, a decrease of approximately 61.53% from the previous close of $2.020. The trading volume has surged to 13.90 million shares, indicating a period of intense market activity and potential volatility for the company. This bearish trend may suggest market sentiment reacting adversely to either recent developments or broader economic factors. Investors are advised to monitor critical support levels around $0.75 and key resistance at $1.00 to better assess future movements of the stock.
In parallel, BriaCell has announced a public offering of units aiming to enhance its financial standing and support the advancement of its innovative cancer immunotherapies. The company priced 12,000,000 units in a best-efforts offering, with each unit comprising one common share or a pre-funded warrant and an accompanying warrant, at a price of $1.25 per unit. This offering is projected to yield gross proceeds of $15 million before expenses. The immediate exercisability of each warrant allows holders to purchase common shares at an exercise price of $1.50, extending over a five-year period.
This funding initiative not only fortifies BriaCell’s financial resources but also underscores its commitment to advancing cancer treatment through novel immunotherapies. The offering is scheduled to close on July 16, 2025, subject to standard closing conditions, and aligns with regulatory compliance under Section 602.1 of the TSX Company Manual. Proceeds from the offering will be utilized for essential working capital and advancing BriaCell’s strategic objectives, highlighting the company’s dedication to transforming cancer care for patients globally.